PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
22942727-2	2012	Preclinical studies indicate that treatment with acetylsalicylic acid + extended-release dipyridamole (ASA + ER-DP) has anti-inflammatory and thereby neuroprotective effects by inhibition of monocyte chemotactic protein-1 (MCP-1) expression.	er-dp	109-114	C-C motif chemokine ligand 2	Homo sapiens	191-221	
22942727-2	2012	Preclinical studies indicate that treatment with acetylsalicylic acid + extended-release dipyridamole (ASA + ER-DP) has anti-inflammatory and thereby neuroprotective effects by inhibition of monocyte chemotactic protein-1 (MCP-1) expression.	er-dp	109-114	C-C motif chemokine ligand 2	Homo sapiens	223-228	
22942727-3	2012	We hypothesized that early treatment with ASA + ER-DP will reduce levels of MCP-1 also in patients with ischemic stroke.	er-dp	48-53	C-C motif chemokine ligand 2	Homo sapiens	76-81	
22942727-8	2012	Comparisons within MCP-1 baseline quartiles indicated that patients in the highest quartile (>217-973 pg/mL) showed improved outcome at 90 days if treated with ASA + ER-DP in comparison to treatment with ASA alone (p = 0.004).	er-dp	169-174	C-C motif chemokine ligand 2	Homo sapiens	19-24